{"name":"Wills Eye","slug":"wills-eye","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Triesence","genericName":"Triesence","slug":"triesence","indication":"Other","status":"marketed"},{"name":"Melphalan, Carboplatin","genericName":"Melphalan, Carboplatin","slug":"melphalan-carboplatin","indication":"Other","status":"phase_1"},{"name":"Use of bromfenac 0.09% to reduce intravitreal injection pain","genericName":"Use of bromfenac 0.09% to reduce intravitreal injection pain","slug":"use-of-bromfenac-0-09-to-reduce-intravitreal-injection-pain","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Triesence","genericName":"Triesence","slug":"triesence","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Melphalan, Carboplatin","genericName":"Melphalan, Carboplatin","slug":"melphalan-carboplatin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Use of bromfenac 0.09% to reduce intravitreal injection pain","genericName":"Use of bromfenac 0.09% to reduce intravitreal injection pain","slug":"use-of-bromfenac-0-09-to-reduce-intravitreal-injection-pain","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQU1VOYS1mZFYwLUIzekFza0lta3BFZGJTTzhhT0VGSnhzNC1RUjhYOTUxX0k1NWdmV3hfREZNc19mUF9rX0xTMXJWU1A4VGxWQTIzaEtrY2lURFN2UlRLeWhxWTBpdUhNM2tsVUZYUUJTd0QzTGVpQnd6UjNBYVBTVFB0SUJWOXRGN0M4UnIxX0ZVd2tzQXBTZnYxbndoVWlNUzVsTFR4bkZjaUFZZ19rb3JPSFcydHoyeGlJUWY3UzU?oc=5","date":"2026-03-02","type":"pipeline","source":"Fierce Pharma","summary":"Amid unfolding Middle East war, pharma giants keep close eye on employee safety, supply chains - Fierce Pharma","headline":"Amid unfolding Middle East war, pharma giants keep close eye on employee safety, supply chains","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNYTFoc3U4bXhRazl4ZDlSR25XeENrdng3d1JFaTd3Q3JfelVIVXBCc01kSGxPcTBvSjRKU2J2bHAzR0ZVZlJLNTJVeVF2WGFnLWNyS1pqdHFDSklFU0hzMEVrbmN2cXc4VWtTZkYzcEZhSlNCNm5rb05oaWh5WnFPQVVZdjZyaldxSEZZZURXSkMtMUk3MHZ6V29CQU9raFRTdkZMYkFBQS1hb01HdWg2eDNfOEZ0MGZWODcyRjJ5czZlaERwcDh4M1NaRHh5cjVmQWVHUlEtSjhrRmo0cmx0aTRXejd6R2tHc285dS13?oc=5","date":"2026-01-16","type":"pipeline","source":"pehub.com","summary":"DFW Capital, GPP, SK Capital eye pharma commercialization; Chicago Bears QB Caleb Williams’ 888 Midas gears up for future investment plays - pehub.com","headline":"DFW Capital, GPP, SK Capital eye pharma commercialization; Chicago Bears QB Caleb Williams’ 888 Midas gears up for futur","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQemVXLWYzckNHbFRlVXRseXJadXBJbV95dGNmRDhXNDB6cnluWTROUk1SLWVHTzRlM1Y4RzNuYnkyR3N5R3VFNGNESWQyWUV0UXBnT3hxN0FfMl8xWGp5bUxyT0FWVmkxY1dZT1BrS0o4RDNybXR5bzJneVdMc1RmbTlJQ0xrUDY5MmpYQnpPRHBuSnpOeG9yZU01aHhQZUFN?oc=5","date":"2026-01-09","type":"regulatory","source":"Medical Marketing and Media","summary":"3 regulatory issues for pharma marketers to keep an eye on in 2026 - Medical Marketing and Media","headline":"3 regulatory issues for pharma marketers to keep an eye on in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQUGhlWU9JbnpUOWhtR1g0U1V3LTE4RVpFZVFyNkZJbGZtVm1OYXJZZFRyRHRhV0thbUpBMk5nTzFlWFlodkZ5TVJ6NUFDblNTbUh3MTBOX3haT2pmZEUzVkJYMnZabkdrYXpZM3o1WmozdTFJbjZhM1RqaDhrYlF3M3NKY0ZlYTNqb2gtTHZyX3EzRUwyRzg0Tlo0Z0UtcTJ5SGdSUjZzZHR0WlU2TDhj?oc=5","date":"2025-12-15","type":"pipeline","source":"Fierce Pharma","summary":"Argenx permanently grounds studies of high-flying Vyvgart in thyroid eye disease - Fierce Pharma","headline":"Argenx permanently grounds studies of high-flying Vyvgart in thyroid eye disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5OS051b2VwWDhmWFBMcE8yWTRWWGlyaElNOUtpSjZrdV9UekFPaDY3RW1rVjlIZjVkeXJPVl9kYno4eWxUOWVuV2ZWNnBvZ20wcTlFWDc1dDBLVUJjOWJ3eFdVdXBKRzJmQURHZDUzb2dJT3hMVHczVw?oc=5","date":"2025-11-24","type":"pipeline","source":"Pharma Voice","summary":"What’s next in the eye disease pipeline? - Pharma Voice","headline":"What’s next in the eye disease pipeline?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPRFYwdEJvMHNmYTIzazRWbGJYVlRTNWV5c0FFdFpzZTQ5Q0o2LXFMQldKWnRoTVMxLUMtNnBkM3BhYnlJLWxPSnVXcFk2MFBQOUxSdllHZDFhdC1HRFlNZEcxUG1BSXJCUUI5ZWdfQlRnTmR3YWg4ejByODVFS1NvNWxWQXlOZG1QU3U0T2NaTjNuQ1d1THFUMUE2eVVzN1Vka3lWTTA3OW5hSUN3ZnJZdkllWVZGb0lrZUxKWHlHMHRYeFZHc3lhUkd5WVU?oc=5","date":"2025-10-07","type":"deal","source":"Los Angeles Times","summary":"Commentary: There's much less than meets the eye in Trump's 'historic' drug price deal with Pfizer - Los Angeles Times","headline":"Commentary: There's much less than meets the eye in Trump's 'historic' drug price deal with Pfizer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPdm5xZGctU1Q1VUowdmZlN092cC13MXEteWJhV1FXM0prV0xEUEdjY0NqS2RIcGdyRDFZNFd3VWd1QVR6Y3BqVDFDZ0t2TEtDV0c5Q2J2LXNkN21VbW1DS2FZNjBERkl6ZWhJbFVQSTBRQ3Jya0UxYU1BZG9xTkRlM1dGZUtpbTlVRzB0V0N2c1RvU0VUSWVVOWxkYmpmeWR3RW5VNFhsSzRMNm9pYl9wOVRoVQ?oc=5","date":"2025-08-12","type":"pipeline","source":"Ophthalmology Times","summary":"Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer - Ophthalmology Times","headline":"Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxORkpOZ0tqNTIwMzBCUG03b01wZ3BvOVpEazFZdngtZ1RBS0JsYWdwenZCeXprM19udGlkMHhSUnE1OWhFc1czR3NGSTR4cGtMbmJCMHVyakpqdkxmNHRNSGIyMFJxRENFWDI3cTFRbnIwUlU3ZktuR054QlNjQkZqakZVeFI1VlJYWlNTOHJRYjQ1VGo3NEI3bzRPTzJCUUNLY0o3T3JLZVptcTVDRlZuckdXbGxFOUJDazJRUURR?oc=5","date":"2025-07-25","type":"pipeline","source":"Eyes On Eyecare","summary":"Leadership watch: PolyActiva, B+L, and Wills Eye make strategic changes - Eyes On Eyecare","headline":"Leadership watch: PolyActiva, B+L, and Wills Eye make strategic changes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPdnJOanpsM3R5cHlyRnpUbjFIMDdRNjJKb05WTzhiYXVyYXhsWEs5WEpuMnF2RnUxOXo5WGtIVDlQZHlycV9pdnJMdEJqRnNYTnNGWHM0Z2xKbXNfR2dsUTgwWUZub2poTGNRYUNtMUg5RmRvYzlTaU9BT1pCY0Z6U1MxaW5ISHJCOHdKTWROOTBXUkRhQzc4cXk5d0lfWWxPTThvVlFUTzJFcGtTbF9tYldn?oc=5","date":"2025-07-17","type":"pipeline","source":"bizjournals.com","summary":"Wills Eye Hospital names new CEO - bizjournals.com","headline":"Wills Eye Hospital names new CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBRcmhiOUNsMGNSbDNObHpPcE54TnlKS2ZFajRFRE5BdWhkMndINjFKSDFIMDJwRlBYb0tZSzUzZG00YnlxekE3U0x0Mkx4YzNQN0dZ?oc=5","date":"2025-03-06","type":"pipeline","source":"FirstWord Pharma","summary":"Luxa's cell therapy 'reverses disease trajectory' in handful of dry AMD patients - FirstWord Pharma","headline":"Luxa's cell therapy 'reverses disease trajectory' in handful of dry AMD patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1qZFRrV2VXSmFEdTdBQ21adUNqTko4Y0xzRkh4aVRrSEVTMkZWeEFWR2JpV1NhM01jOEk5alBXUDFnSXcyTTNNdkdlUWszZzZMMnlZT2cza2NUV3VESWF4RDFuY2lPYzE3X3djbHBoS0tvS0ZzNGxv?oc=5","date":"2023-07-21","type":"pipeline","source":"EyeWorld","summary":"Lindstrom Lecture and symposium recap - EyeWorld","headline":"Lindstrom Lecture and symposium recap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNem5MYXVvUkN5cnFDM1RNTVY3Q1JwMEt0WWl2dExlbXh4el9qR0NxVG9sUERrTi1GYUpyVDRGckVBR3Q1RXd0QzBSVnhMV3d3YWlYQnZxMXJGMVNSSy1Vb2Q2emoyZnRCQTg3TnZwVEZObDdTOExIUE1fUXdvYmc3dUhxQjM1Y1ZLMmdaZ1RtRDRKak5ORnpLWVNWMHMySnFyUEhncmx1ampadURHa0FYWGJaeXQ2R1U?oc=5","date":"2018-08-14","type":"pipeline","source":"PR Newswire","summary":"Wills Eye Hospital Earns National Recognition for Excellence - PR Newswire","headline":"Wills Eye Hospital Earns National Recognition for Excellence","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}